BIOTICA BIOQUIMICA ANALITICA SL

Their core work

Biotica is a Spanish bioanalytical SME specializing in rapid immunoanalysis-based detection systems for waterborne pathogens, with a focused track record in Legionella pneumophila sensing. Their flagship product, ULISENS, is an early-warning detection system that uses immunological methods to identify Legionella contamination in water installations — cooling towers, hospital plumbing, and public water networks — before it reaches dangerous concentrations. They successfully completed the full EU SME Instrument progression, moving from Phase 1 feasibility (2015) to a Phase 2 product development grant (2016–2018), which signals a commercially mature, market-ready trajectory rather than pure research. Their business sits at the intersection of analytical chemistry, public health compliance, and water safety diagnostics.

What they specialise in

How they've shifted over time

Biotica's H2020 record covers a single technology developed across two funding phases, so there is no pivot or broadening of focus — only deepening. In 2015 they validated the technical and commercial feasibility of ULISENS under SME Phase 1; by 2016–2018 they had secured nearly €769k to develop the full product, indicating the concept passed market assessment. The absence of any subsequent H2020 activity after 2018 likely means they exited into product commercialization rather than continuing in research funding — a common trajectory for successful SME Instrument companies.

Biotica appears to have completed its R&D funding cycle and moved toward market deployment of ULISENS; any future collaboration would likely involve technology licensing, distribution partnerships, or integration into broader water safety monitoring platforms rather than basic research.

How they like to work

Biotica has operated exclusively as a sole coordinator — both projects were SME Instrument applications, a funding scheme designed for individual companies rather than multi-partner consortia. This means they have no recorded consortium experience and no documented network of academic or industrial partners within H2020. Working with them would mean engaging directly with the company as a product developer or technology provider, not as a consortium research partner.

Biotica has no recorded consortium partners in H2020 — both grants were solo SME Instrument awards. Their collaboration footprint is entirely domestic and self-contained, with no documented cross-border research ties.

What sets them apart

Biotica holds a rare combination: a commercially validated, EU-funded Legionella rapid detection product developed by a lean SME with full ownership of the IP — no academic consortium to negotiate with. For companies or public bodies in water safety, facilities management, or environmental health that need a ready diagnostic tool rather than a research partner, this makes Biotica a direct technology acquisition or licensing target. Their Castellon base and Spanish SME status also makes them an attractive partner for consortia needing a southern European industrial end-user or technology integrator in health diagnostics projects.

Highlights from their portfolio

• ULISENS
  The SME-2 award of €768,929 (2016–2018) represents a full product development grant for a Legionella immunosensor — one of the highest-value Phase 2 SME Instrument grants, signaling strong commercial validation by EU evaluators.
• ULISENS
  The Phase 1 feasibility award (2015, €50k) and subsequent Phase 2 win demonstrate a clean sequential SME Instrument success story, which is statistically uncommon and indicates a robust business case.